Ser236
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser236  -  S6 (human)

Site Information
AKRRRLssLRAstsK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448093
Available spectra:  6 CST
Associated spectra:  10 CST

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 54 ) , flow cytometry ( 89 ) , immunoassay ( 11 , 14 , 15 , 98 , 112 , 124 , 131 , 352 ) , immunoprecipitation ( 21 , 52 , 131 , 185 , 854 ) , mass spectrometry ( 25 , 32 , 34 , 39 , 42 , 50 , 52 , 53 , 54 , 58 , 61 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 75 , 78 , 79 , 81 , 83 , 84 , 85 , 86 , 88 , 90 , 92 , 93 , 94 , 95 , 96 , 97 , 99 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 122 , 123 , 125 , 126 , 127 , 128 , 129 , 130 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 235 , 236 , 237 , 238 , 239 , 240 , 241 , 242 , 245 , 246 , 247 , 248 , 249 , 250 , 251 , 252 , 253 , 254 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 278 , 280 , 281 , 282 , 283 , 284 , 285 , 286 , 287 , 288 , 289 , 290 , 291 , 293 , 294 , 296 , 297 , 298 , 299 , 300 , 301 , 302 , 303 , 304 , 305 , 306 , 307 , 308 , 310 , 311 , 312 , 313 , 314 , 316 , 317 , 318 , 319 , 320 , 321 , 322 , 323 , 324 , 326 , 327 , 328 , 329 , 330 , 331 , 332 , 333 , 336 , 337 , 338 , 339 , 340 , 341 , 342 , 343 , 344 , 345 , 346 , 347 , 351 , 353 , 354 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 , 367 , 368 , 369 , 370 , 371 , 372 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 382 , 383 , 384 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 401 , 402 , 403 , 404 , 405 , 406 , 407 , 408 , 409 , 410 , 411 , 412 , 413 , 414 , 415 , 416 , 417 , 418 , 419 , 420 , 421 , 423 , 424 , 425 , 426 , 427 , 428 , 429 , 430 , 431 , 432 , 433 , 434 , 435 , 436 , 437 , 438 , 439 , 440 , 442 , 443 , 444 , 445 , 446 , 447 , 448 , 449 , 450 , 451 , 452 , 453 , 454 , 455 , 456 , 457 , 458 , 459 , 460 , 461 , 462 , 463 , 464 , 465 , 466 , 467 , 468 , 469 , 470 , 471 , 472 , 473 , 474 , 475 , 476 , 477 , 478 , 479 , 480 , 481 , 482 , 483 , 484 , 485 , 486 , 487 , 488 , 489 , 490 , 491 , 492 , 493 , 494 , 495 , 496 , 497 , 498 , 499 , 500 , 501 , 502 , 503 , 504 , 505 , 506 , 507 , 508 , 509 , 510 , 511 , 512 , 513 , 514 , 515 , 516 , 517 , 518 , 519 , 520 , 521 , 522 , 523 , 524 , 525 , 526 , 527 , 528 , 529 , 530 , 531 , 532 , 533 , 534 , 535 , 537 , 538 , 539 , 540 , 541 , 542 , 543 , 544 , 545 , 546 , 547 , 548 , 549 , 550 , 551 , 552 , 553 , 554 , 555 , 556 , 557 , 558 , 559 , 560 , 561 , 562 , 563 , 564 , 565 , 566 , 567 , 568 , 569 , 570 , 571 , 572 , 573 , 574 , 575 , 577 , 578 , 579 , 580 , 581 , 582 , 583 , 584 , 585 , 586 , 587 , 588 , 589 , 590 , 591 , 592 , 593 , 594 , 595 , 596 , 597 , 598 , 599 , 600 , 601 , 602 , 603 , 604 , 605 , 606 , 607 , 608 , 609 , 610 , 611 , 612 , 613 , 614 , 615 , 616 , 617 , 618 , 619 , 620 , 621 , 622 , 623 , 624 , 625 , 626 , 627 , 628 , 629 , 630 , 631 , 632 , 633 , 634 , 635 , 636 , 637 , 638 , 639 , 640 , 641 , 642 , 643 , 644 , 645 , 646 , 647 , 648 , 649 , 650 , 651 , 652 , 653 , 654 , 655 , 656 , 657 , 658 , 659 , 660 , 661 , 662 , 663 , 664 , 665 , 666 , 667 , 669 , 670 , 671 , 672 , 673 , 674 , 675 , 676 , 677 , 678 , 679 , 680 , 681 , 682 , 683 , 684 , 685 , 686 , 687 , 688 , 689 , 690 , 691 , 692 , 693 , 694 , 695 , 696 , 697 , 698 , 699 , 700 , 701 , 702 , 703 , 704 , 705 , 706 , 707 , 708 , 709 , 710 , 711 , 712 , 713 , 714 , 715 , 716 , 717 , 718 , 719 , 720 , 721 , 722 , 723 , 725 , 726 , 727 , 728 , 729 , 730 , 731 , 732 , 733 , 734 , 735 , 736 , 737 , 738 , 739 , 740 , 741 , 742 , 743 , 744 , 745 , 746 , 747 , 748 , 749 , 750 , 752 , 753 , 754 , 755 , 756 , 757 , 758 , 759 , 760 , 761 , 762 , 763 , 764 , 765 , 766 , 767 , 768 , 769 , 770 , 771 , 772 , 773 , 774 , 775 , 776 , 777 , 778 , 779 , 780 , 781 , 782 , 783 , 784 , 785 , 786 , 787 , 788 , 789 , 790 , 791 , 792 , 793 , 794 , 795 , 796 , 797 , 798 , 799 , 800 , 801 , 802 , 803 , 804 , 805 , 806 , 807 , 808 , 809 , 812 , 813 , 815 , 816 , 817 , 818 , 819 , 820 , 821 , 822 , 824 , 825 , 826 , 827 , 828 , 829 , 830 , 831 , 832 , 833 , 834 , 835 , 836 , 837 , 838 , 839 , 840 , 841 , 842 , 843 , 844 , 845 , 846 , 847 , 848 , 849 , 850 , 851 , 852 , 853 , 855 , 856 , 857 , 858 , 859 , 860 , 861 , 862 , 863 , 864 , 865 , 866 , 867 , 868 , 869 , 870 , 871 , 872 , 873 , 874 , 875 , 876 , 877 , 878 , 879 , 881 , 882 , 883 , 884 , 886 , 887 , 888 , 889 , 890 , 891 , 892 , 893 , 894 , 895 , 896 , 897 , 898 , 899 , 900 , 901 , 902 , 903 , 904 , 905 , 906 , 907 , 908 , 909 , 910 , 911 , 912 , 913 , 914 , 915 , 916 , 917 , 918 , 919 , 920 , 921 , 922 , 923 , 924 , 925 , 926 , 927 , 928 , 929 , 930 , 931 , 932 , 934 , 935 , 936 , 937 , 938 , 939 , 940 , 941 , 942 , 943 , 944 , 945 , 946 , 947 , 948 , 949 , 950 , 951 , 952 , 953 , 954 , 955 , 956 , 957 , 958 , 959 , 960 , 961 , 962 , 963 , 964 , 965 , 966 , 967 , 968 , 969 , 970 , 971 , 972 , 973 , 974 , 975 , 976 , 977 , 978 , 979 , 980 , 981 , 982 , 983 , 984 , 985 , 986 , 987 , 988 , 989 , 990 , 991 , 992 , 993 , 994 , 996 , 997 , 998 , 999 , 1000 , 1001 , 1002 , 1003 , 1004 , 1005 , 1006 , 1007 , 1008 , 1009 , 1010 , 1011 , 1012 , 1013 , 1014 , 1015 , 1017 , 1018 , 1019 , 1021 , 1022 , 1023 , 1024 , 1025 , 1026 , 1027 , 1028 , 1030 , 1032 , 1033 , 1034 , 1035 , 1042 , 1045 , 1046 , 1047 , 1048 , 1049 ) , mutation of modification site ( 21 , 24 , 52 , 854 , 933 , 1016 , 1038 , 1040 ) , peptide sequencing ( 26 ) , phospho-antibody ( 10 , 11 , 12 , 13 , 14 , 15 , 16 , 19 , 20 , 21 , 22 , 23 , 24 , 26 , 27 , 29 , 30 , 31 , 33 , 35 , 37 , 38 , 40 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 51 , 52 , 54 , 55 , 56 , 57 , 60 , 62 , 74 , 80 , 82 , 91 , 98 , 100 , 101 , 112 , 121 , 124 , 131 , 132 , 161 , 174 , 185 , 194 , 243 , 244 , 279 , 295 , 309 , 315 , 325 , 334 , 335 , 339 , 348 , 349 , 350 , 352 , 422 , 536 , 576 , 668 , 751 , 810 , 814 , 823 , 880 , 885 , 933 , 995 , 1016 , 1020 , 1029 , 1031 , 1036 , 1037 , 1038 , 1039 , 1040 , 1041 , 1043 , 1044 , 1050 , 1051 , 1052 , 1054 , 1056 , 1057 , 1058 , 1060 , 1061 ) , phosphoamino acid analysis ( 724 ) , western blotting ( 10 , 12 , 13 , 15 , 16 , 19 , 20 , 21 , 22 , 23 , 24 , 26 , 27 , 29 , 30 , 31 , 33 , 35 , 37 , 38 , 40 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 51 , 52 , 54 , 55 , 56 , 57 , 60 , 62 , 74 , 80 , 82 , 91 , 98 , 100 , 101 , 112 , 121 , 131 , 132 , 161 , 174 , 185 , 194 , 243 , 244 , 279 , 295 , 309 , 315 , 325 , 334 , 335 , 339 , 348 , 349 , 352 , 422 , 536 , 576 , 668 , 724 , 751 , 810 , 814 , 823 , 854 , 880 , 885 , 933 , 995 , 1016 , 1020 , 1029 , 1031 , 1036 , 1037 , 1038 , 1039 , 1040 , 1041 , 1043 , 1044 , 1051 , 1052 , 1054 , 1058 , 1061 )
Disease tissue studied:
bone cancer ( 349 , 1043 ) , brain cancer ( 27 , 112 , 295 , 315 , 349 , 1029 , 1036 ) , glioblastoma ( 27 , 112 , 315 , 349 , 1029 , 1036 ) , glioblastoma multiforme ( 1036 ) , glioma ( 27 , 112 , 315 , 349 , 1029 , 1036 ) , Schwannoma ( 295 ) , breast cancer ( 23 , 26 , 32 , 33 , 35 , 45 , 53 , 56 , 57 , 84 , 112 , 161 , 244 , 348 , 349 , 654 , 655 , 1037 , 1044 , 1051 ) , breast cancer, triple negative ( 56 , 112 ) , cervical cancer ( 161 ) , colorectal cancer ( 13 , 31 , 122 , 123 , 161 , 469 , 476 , 477 , 479 ) , colorectal carcinoma ( 31 , 122 , 123 , 161 ) , endometrial cancer ( 194 ) , endometrial adenocarcinoma ( 194 ) , esophageal cancer ( 14 ) , esophageal carcinoma ( 14 ) , gallbladder cancer ( 628 ) , gallbladder carcinoma ( 628 ) , gastric cancer ( 93 , 94 , 95 , 97 , 125 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 166 , 171 , 172 , 173 , 232 , 233 , 234 , 235 , 236 , 237 , 238 , 240 , 271 , 272 , 273 , 277 , 278 , 283 , 284 , 299 , 314 , 318 , 344 , 345 , 351 , 629 , 698 , 738 , 739 , 940 , 943 , 944 , 945 ) , gastric carcinoma ( 93 , 94 , 95 , 97 , 125 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 166 , 171 , 172 , 173 , 232 , 233 , 234 , 235 , 236 , 237 , 238 , 240 , 271 , 272 , 273 , 277 , 278 , 283 , 284 , 299 , 314 , 318 , 344 , 345 , 351 , 698 , 738 , 739 , 940 , 943 , 944 , 945 ) , gastric carcinoma, surrounding tissue ( 812 ) , HNSCC ( 51 ) , kidney cancer ( 40 , 576 , 751 ) , leukemia ( 20 , 22 , 29 , 54 , 89 , 96 , 98 , 269 , 270 , 279 , 310 , 312 , 382 , 383 , 402 , 500 , 657 , 658 , 659 , 660 , 661 , 712 , 713 , 714 , 827 , 828 , 829 , 838 , 839 , 989 , 1015 , 1031 , 1040 , 1051 ) , acute myelogenous leukemia ( 54 , 89 , 96 , 382 , 383 , 402 , 1051 ) , chronic lymphocytic leukemia ( 22 ) , chronic myelogenous leukemia ( 10 , 29 , 269 , 270 , 279 , 310 , 312 , 500 , 657 , 658 , 659 , 660 , 661 , 712 , 713 , 714 , 827 , 828 , 829 , 838 , 839 , 989 , 1015 , 1031 ) , T cell leukemia ( 20 , 22 , 98 , 1040 ) , liver cancer ( 15 , 19 , 353 , 627 , 751 ) , hepatocellular carcinoma ( 15 , 19 ) , lung cancer ( 31 , 38 , 44 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 72 , 73 , 147 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 186 , 187 , 188 , 189 , 190 , 191 , 198 , 239 , 274 , 275 , 276 , 285 , 286 , 294 , 319 , 324 , 346 , 349 , 351 , 384 , 491 , 499 , 501 , 502 , 581 , 583 , 633 , 691 , 692 , 736 , 737 , 825 , 934 , 935 , 936 , 937 , 938 , 939 , 941 , 942 , 985 , 986 , 987 , 988 , 990 ) , mesothelioma ( 179 , 189 ) , non-small cell lung cancer ( 31 , 38 , 44 , 65 , 66 , 67 , 69 , 70 , 72 , 78 , 79 , 147 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 186 , 187 , 188 , 189 , 190 , 191 , 239 , 274 , 275 , 276 , 285 , 286 , 294 , 319 , 324 , 346 , 384 , 491 , 499 , 581 , 583 , 691 , 692 , 736 , 737 , 825 , 934 , 935 , 936 , 937 , 938 , 939 , 941 , 942 , 985 , 986 , 987 , 988 , 990 ) , non-small cell lung adenocarcinoma ( 38 , 65 , 66 , 67 , 68 , 69 , 70 , 72 , 73 , 79 , 147 , 177 , 180 , 182 , 183 , 184 , 187 , 188 , 190 , 275 , 285 , 286 , 319 , 324 , 351 , 499 , 583 , 691 , 692 , 736 , 737 ) , non-small cell lung adenocarcinoma, surrounding tissue ( 582 ) , non-small cell large cell lung carcinoma ( 66 , 69 , 181 ) , non-small cell squamous cell lung carcinoma ( 68 , 178 , 179 , 186 , 189 , 275 , 319 , 324 , 351 , 501 , 502 , 633 , 736 , 737 , 825 , 934 , 935 , 937 , 939 ) , non-small cell squamous cell lung carcinoma, surrounding tissue ( 632 ) , small-cell lung cancer ( 63 , 64 ) , lymphoma ( 20 , 24 , 48 , 98 , 121 , 309 ) , anaplastic large cell lymphoma ( 309 ) , B cell lymphoma ( 24 , 48 , 98 ) , Hodgkin's lymphoma ( 20 ) , non-Hodgkin's lymphoma ( 24 , 48 , 98 ) , mantle cell lymphoma ( 24 , 48 , 98 ) , PEL ( 121 ) , T cell lymphoma ( 309 ) , neuroblastoma ( 42 , 83 , 174 , 288 , 289 , 290 , 326 , 327 , 328 , 329 , 529 , 530 , 1029 ) , ovarian cancer ( 112 , 132 , 161 , 197 , 295 , 1055 ) , pancreatic cancer ( 1052 ) , pancreatic carcinoma ( 1052 ) , pancreatic ductal adenocarcinoma ( 61 ) , prostate cancer ( 132 , 161 , 453 ) , Kaposi's sarcoma ( 121 ) , melanoma skin cancer ( 39 , 52 , 368 , 369 , 370 , 498 , 503 , 504 , 505 , 507 , 630 , 631 , 651 , 652 , 653 , 662 , 663 ) , leiomyosarcoma ( 194 ) , rhabdomyosarcoma ( 43 ) , cancer, squamous cell carcinoma ( 19 ) , teratoma ( 300 , 313 ) , neurofibromatosis type 1 ( 335 ) , tuberous sclerosis ( 751 )
Relevant cell line - cell type - tissue:
'blood, serum' ( 683 , 684 , 685 , 686 ) , 'granulosa, luteal' ( 325 ) , 'muscle, skeletal' ( 62 , 99 , 1056 ) , 'neuron, cortical'-brain ( 131 ) , 'pancreatic, ductal'-pancreas ( 61 ) , 'stem, embryonic' ( 91 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 282 ) , 293 (epithelial) [AT1 (human), transfection] ( 245 ) , 293 (epithelial) [Raptor (human), transfection] ( 185 ) , 293 (epithelial) ( 10 , 52 , 57 , 112 , 291 , 334 , 349 , 352 , 422 , 528 , 532 , 533 , 534 , 535 , 537 , 538 , 539 , 540 , 541 , 542 , 543 , 567 , 668 , 724 , 854 , 1038 ) , 293E (epithelial) ( 933 ) , 786-O (renal) [VHL (human), transfection] ( 34 ) , 786-O (renal) ( 40 ) , A2780 (ovarian) ( 161 ) , A375 (melanocyte) ( 52 ) , A431 (epithelial) ( 885 ) , A498 (renal) ( 293 ) , A549 (pulmonary) [LKB1 (human), no information] ( 692 ) , A549 (pulmonary) ( 38 , 65 , 349 , 691 ) , AN3-CA (endometrial) ( 194 ) , B lymphocyte-blood ( 1040 ) , BaF3 ('B lymphocyte, precursor') ( 279 ) , bone marrow ( 37 , 382 , 383 , 402 ) , brain ( 16 , 1029 ) , breast ( 654 , 655 ) , BT-20 (breast cell) ( 112 ) , BT-474 (breast cell) ( 26 , 32 , 161 ) , BV-173 (myeloid) ( 279 , 1031 ) , C33-A (cervical) ( 161 ) , Caki-1 (renal) ( 576 ) , Cal-12T (pulmonary) ( 72 ) , CAL-72 ( 15 ) , Cal27 (squamous) ( 51 ) , Calu-3 (pulmonary) ( 67 ) , Capan2 (pancreatic) ( 30 ) , CEF ( 21 ) , CL1-0 (pulmonary) ( 198 ) , CL1-1 (pulmonary) ( 198 ) , CL1-2 (pulmonary) ( 198 ) , CL1-5 (pulmonary) ( 198 ) , COLO-829 (melanocyte) ( 52 ) , colon ( 469 , 476 , 477 , 479 ) , COS (fibroblast) ( 926 , 1016 ) , COS7 (fibroblast) ( 55 ) , CT26 (epithelial) ( 13 ) , DMS153 (pulmonary) ( 70 ) , DMS53 (pulmonary) ( 64 ) , DMS79 (pulmonary) ( 63 ) , DU 145 (prostate cell) ( 885 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 86 ) , Flp-In T-Rex-293 (epithelial) ( 86 ) , glial ( 751 ) , GRANTA-519 (B lymphocyte) ( 24 ) , granulocyte-blood ( 89 ) , HaCaT (keratinocyte) ( 60 ) , HAEC (endothelial) ( 810 ) , HAP1 ( 10 ) , HCC1428 (breast cell) ( 23 ) , HCC15 (pulmonary) ( 68 ) , HCC1500 (breast cell) ( 23 ) , HCC1806 (breast cell) ( 56 ) , HCC44 (pulmonary) ( 72 ) , HCC78 (pulmonary) ( 69 ) , HCC827 (pulmonary) ( 67 ) , HCT116 (intestinal) ( 31 , 122 , 123 , 161 ) , HDLM-2 (lymphoid) ( 20 ) , heart ( 1061 ) , HEC-1-A (endometrial) ( 194 ) , HEC-50B (endometrial) ( 194 ) , HEI-193 (Schwann) ( 295 ) , HEK293-A (epithelial) ( 11 ) , HEK293T (epithelial) ( 80 , 100 , 101 , 995 , 1016 , 1027 ) , HeLa (cervical) ( 10 , 25 , 43 , 47 , 50 , 74 , 81 , 131 , 157 , 193 , 315 , 320 , 321 , 322 , 323 , 339 , 367 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 401 , 403 , 404 , 405 , 406 , 407 , 408 , 409 , 410 , 411 , 412 , 413 , 414 , 415 , 416 , 417 , 418 , 419 , 420 , 421 , 423 , 424 , 425 , 426 , 427 , 428 , 429 , 430 , 431 , 432 , 433 , 434 , 506 , 508 , 509 , 510 , 511 , 512 , 513 , 514 , 515 , 516 , 517 , 518 , 519 , 520 , 521 , 522 , 523 , 524 , 525 , 536 , 679 , 688 , 885 , 933 , 1030 ) , HeLa S3 (cervical) ( 175 ) , Hep3B (hepatic) ( 19 ) , HepG2 (hepatic) ( 440 , 442 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 53 ) , HMLER ('stem, breast cancer') ( 53 ) , HMVEC (endothelial) ( 1060 ) , Hs852.T (melanocyte) ( 52 ) , HT-29 (intestinal) ( 1049 ) , hTERT-RPE1 (epithelial) ( 352 ) , HUES-9 ('stem, embryonic') ( 192 ) , Huh7 (hepatic) ( 19 , 627 ) , IMR32 (neural crest) ( 1029 ) , Ishikawa (endometrial) ( 194 ) , JEKO-1 (B lymphocyte) ( 24 , 48 , 98 ) , Jurkat (T lymphocyte) ( 20 , 22 , 71 , 75 , 88 , 90 , 92 , 98 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 126 , 127 , 128 , 129 , 130 , 133 , 158 , 159 , 160 , 162 , 163 , 164 , 165 , 167 , 168 , 169 , 170 , 176 , 195 , 196 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 241 , 242 , 243 , 246 , 247 , 248 , 249 , 250 , 251 , 252 , 253 , 254 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 268 , 280 , 281 , 296 , 297 , 298 , 302 , 303 , 304 , 305 , 306 , 307 , 308 , 311 , 316 , 317 , 330 , 331 , 332 , 333 , 336 , 337 , 338 , 340 , 341 , 342 , 343 , 347 , 354 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 , 371 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 443 , 444 , 445 , 446 , 447 , 448 , 449 , 450 , 451 , 452 , 457 , 458 , 459 , 460 , 461 , 462 , 463 , 464 , 465 , 466 , 467 , 468 , 470 , 471 , 472 , 473 , 474 , 475 , 478 , 480 , 481 , 482 , 483 , 484 , 485 , 486 , 492 , 493 , 494 , 495 , 496 , 497 , 531 , 552 , 553 , 554 , 555 , 556 , 557 , 558 , 559 , 560 , 561 , 562 , 563 , 564 , 565 , 566 , 577 , 578 , 587 , 606 , 607 , 608 , 609 , 610 , 611 , 612 , 613 , 638 , 639 , 640 , 641 , 642 , 643 , 650 , 656 , 680 , 681 , 682 , 687 , 690 , 705 , 706 , 707 , 708 , 709 , 710 , 711 , 715 , 716 , 717 , 718 , 719 , 776 , 777 , 778 , 783 , 807 , 808 , 809 , 813 , 815 , 824 , 826 , 830 , 831 , 832 , 833 , 834 , 835 , 836 , 837 , 842 , 843 , 844 , 845 , 877 , 878 , 879 , 889 , 890 , 891 , 892 , 893 , 894 , 895 , 896 , 897 , 898 , 899 , 900 , 901 , 902 , 903 , 904 , 905 , 914 , 915 , 916 , 917 , 927 , 928 , 929 , 930 , 931 , 932 , 958 , 959 , 960 , 961 , 962 , 971 , 972 , 973 , 974 , 975 , 976 , 977 , 978 , 993 , 994 , 1003 , 1004 , 1005 , 1017 , 1021 , 1022 , 1023 , 1024 , 1025 , 1026 , 1028 , 1045 , 1046 , 1047 , 1054 ) , K562 (erythroid) ( 29 , 81 , 269 , 270 , 279 , 310 , 312 , 438 , 439 , 500 , 657 , 658 , 659 , 660 , 661 , 689 , 712 , 713 , 714 , 827 , 828 , 829 , 838 , 839 , 840 , 841 , 846 , 847 , 881 , 882 , 883 , 884 , 887 , 888 , 906 , 907 , 908 , 909 , 910 , 911 , 912 , 913 , 963 , 964 , 965 , 966 , 967 , 968 , 969 , 970 , 982 , 989 , 996 , 997 , 998 , 999 , 1000 , 1001 , 1002 , 1006 , 1007 , 1008 , 1009 , 1010 , 1011 , 1012 , 1013 , 1014 , 1015 , 1018 , 1019 , 1031 , 1050 ) , Karpas-299 (T lymphocyte) ( 309 ) , KCL22 (myeloid) ( 29 ) , KELLY (neural crest) ( 1029 ) , KG-1 (myeloid) ( 96 ) , kidney ( 352 , 576 , 751 ) , Kit225 (T lymphocyte) ( 1040 ) , KLE (endometrial) ( 194 ) , KM-H2 (lymphoid) ( 20 ) , KPL-1 (breast cell) ( 161 ) , Kyse150 (esophageal) ( 14 ) , Kyse30 (esophageal) ( 14 ) , Kyse410 (esophageal) ( 14 ) , L1236 (lymphoid) ( 20 ) , L428 (lymphoid) ( 20 ) , L540 (lymphoid) ( 20 ) , LAMA84 (myeloid) ( 1050 ) , LAN-6 (neural crest) ( 42 , 288 , 326 , 529 , 530 ) , liver ( 58 , 353 , 751 ) , LLC-PK1 (renal) ( 1039 ) , LN229 (glial) ( 27 ) , LNCaP (prostate cell) ( 453 ) , LOU-NH91 (squamous) ( 68 , 178 ) , LS-513 (intestinal) ( 161 ) , lung ( 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 72 , 73 , 346 , 350 , 384 , 491 , 501 , 502 , 581 , 582 , 583 , 632 , 633 ) , lymphocyte-blood ( 89 ) , lymphoid ( 98 ) , M059K (glial) ( 1032 , 1033 , 1034 , 1035 , 1042 , 1048 ) , MCF-10A (breast cell) ( 35 , 57 ) , MCF-7 (breast cell) ( 23 , 32 , 35 , 45 , 57 , 161 , 348 , 349 , 885 , 1037 , 1044 , 1051 ) , MDA-MB-231 (breast cell) ( 26 , 45 , 161 ) , MEF (fibroblast) [Etk (human), heterozygous knockout] ( 82 ) , MEF (fibroblast) [TSC22D2 (human)] ( 885 ) , MEF (fibroblast) ( 35 , 47 , 100 , 131 , 334 , 751 , 1038 ) , MIA PaCa (pancreatic) ( 885 ) , MKN-45 (gastric) ( 85 , 93 , 94 , 95 , 97 , 125 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 166 , 171 , 172 , 173 , 232 , 233 , 234 , 235 , 236 , 237 , 238 , 240 , 271 , 272 , 273 , 277 , 278 , 283 , 284 , 299 , 314 , 318 , 344 , 345 , 351 , 487 , 488 , 489 , 490 , 579 , 580 , 614 , 615 , 616 , 617 , 618 , 619 , 620 , 621 , 622 , 623 , 624 , 625 , 626 , 644 , 645 , 646 , 647 , 648 , 649 , 664 , 665 , 693 , 694 , 695 , 696 , 697 , 698 , 699 , 700 , 701 , 702 , 703 , 704 , 738 , 739 , 816 , 817 , 886 , 918 , 919 , 920 , 921 , 922 , 923 , 924 , 925 , 940 , 943 , 944 , 945 , 950 , 951 , 956 , 957 , 983 , 984 , 991 , 992 ) , mononuclear-blood ( 22 ) , MV4-11 (macrophage) ( 436 , 437 ) , myeloid-bone marrow ( 37 ) , myocyte-heart ( 1058 ) , NB-4 (myeloid) ( 54 , 1051 , 1057 ) , NB10 (neural crest) ( 83 ) , NCCIT (epithelial) ( 300 , 313 ) , NCI-H128 (pulmonary) ( 63 ) , NCI-H1299 (pulmonary) ( 31 , 66 ) , NCI-H1355 (pulmonary) ( 65 ) , NCI-H1417 (pulmonary) ( 63 ) , NCI-H1437 (pulmonary) ( 70 , 72 ) , NCI-H1563 (pulmonary) ( 180 ) , NCI-H157 (pulmonary) ( 31 ) , NCI-H1650 (pulmonary) ( 67 , 294 , 372 , 373 ) , NCI-H1651 (pulmonary) ( 191 ) , NCI-H1666 (pulmonary) ( 72 , 183 ) , NCI-H1703 (squamous) ( 68 , 85 , 275 , 319 , 324 , 351 , 454 , 455 , 456 , 544 , 545 , 546 , 547 , 548 , 549 , 550 , 551 , 568 , 569 , 570 , 571 , 572 , 573 , 574 , 575 , 634 , 635 , 636 , 637 , 666 , 667 , 669 , 670 , 671 , 672 , 673 , 674 , 675 , 676 , 677 , 678 , 736 , 737 , 825 , 934 , 935 , 937 , 939 , 946 , 947 , 952 , 953 , 979 , 980 , 985 , 986 ) , NCI-H1734 (pulmonary) ( 66 ) , NCI-H1781 (pulmonary) ( 69 ) , NCI-H1792 (pulmonary) ( 65 ) , NCI-H1944 (pulmonary) ( 66 , 190 ) , NCI-H1975 (pulmonary) ( 67 ) , NCI-H2073 (pulmonary) ( 68 , 70 , 177 ) , NCI-H209 (pulmonary) ( 63 , 70 ) , NCI-H2106 (pulmonary) ( 67 ) , NCI-H2170 (squamous) ( 186 ) , NCI-H2228 (pulmonary) ( 69 , 79 , 499 , 590 ) , NCI-H226 (pulmonary) ( 179 , 189 ) , NCI-H23 (pulmonary) ( 65 ) , NCI-H2342 (pulmonary) ( 68 , 182 , 188 ) , NCI-H2405 (pulmonary) ( 72 ) , NCI-H3122 (pulmonary) ( 69 , 78 , 147 , 184 , 187 ) , NCI-H3255 (pulmonary) ( 85 , 239 , 274 , 276 , 351 , 592 , 593 , 594 , 595 , 596 , 597 , 598 , 599 , 600 , 601 , 602 , 603 , 604 , 605 , 936 , 938 , 941 , 942 , 948 , 949 , 954 , 955 , 981 , 987 , 988 , 990 ) , NCI-H358 (pulmonary) ( 66 ) , NCI-H441 (pulmonary) ( 65 , 285 , 286 ) , NCI-H446 (pulmonary) ( 64 ) , NCI-H460 (pulmonary) ( 66 , 885 ) , NCI-H524 (pulmonary) ( 63 ) , NCI-H526 (pulmonary) ( 64 ) , NCI-H661 (pulmonary) ( 69 , 181 ) , NCI-H69 (pulmonary) ( 64 ) , NCI-H82 (pulmonary) ( 64 ) , NCI-H838 (pulmonary) ( 70 ) , neuron-'brain, cerebral cortex' ( 1016 ) , NPC (neural crest) ( 83 ) , NT2 (testicular) ( 301 ) , OCUG-1 ( 628 ) , oocyte ( 880 ) , ovarian ( 880 ) , ovary ( 1055 ) , OVCAR3 (ovarian) ( 132 ) , OVCAR4 (ovarian) ( 1055 ) , OVCAR5 (ovarian) ( 1055 ) , OVKATE (ovarian) ( 197 ) , pancreas ( 1052 ) , PC3 (prostate cell) ( 132 , 161 , 885 ) , PEER ( 15 ) , prostate ( 124 ) , RCC4 (renal) ( 576 ) , Rh30 ('muscle, skeletal') ( 43 ) , salivary gland ( 526 , 527 ) , SEM (B lymphocyte) ( 435 ) , SH-SY5Y (neural crest) ( 42 , 174 , 290 , 328 , 329 , 1029 ) , SHEP (neuron) ( 1029 ) , SK-N-BE(2) (neural crest) ( 42 , 1029 ) , SKBr3 (breast cell) ( 26 , 84 ) , skin ( 368 , 369 , 370 , 498 , 503 , 504 , 505 , 507 , 630 , 631 , 651 , 652 , 653 , 662 , 663 ) , SKNSH (neural crest) ( 1029 ) , SKOV-3 (ovarian) ( 112 , 132 , 295 , 1055 ) , SKUT-1 ( 194 ) , SMS-KCN-A (neural crest) ( 42 , 289 , 327 ) , SNU-398 (hepatic) ( 15 ) , SNU-878 ( 15 ) , SNU-886 ( 15 ) , SR (T lymphocyte) ( 309 ) , ST88-14 (neuron) ( 335 ) , stomach ( 629 , 812 ) , SU-DHL1 (T lymphocyte) ( 309 ) , SW1463 (intestinal) ( 161 ) , T lymphocyte ( 12 ) , T lymphocyte-blood ( 1020 , 1040 ) , T47D (breast cell) ( 23 , 33 , 161 , 244 ) , T98G (glial) ( 1036 ) , U-251 MG (glial) ( 315 ) , U2OS (bone cell) ( 349 , 1043 ) , U87MG (glial) ( 112 , 349 , 1029 ) , UMUC6 (bladder cell) ( 51 ) , vascular smooth muscle cell ('muscle, smooth') ( 823 ) , VSMC-aorta ( 1041 ) , WM239A (melanocyte) ( 39 ) , Z138 (B lymphocyte) ( 48 )

Upstream Regulation
Regulatory protein:
ACSL4 (human) ( 33 ) , Akt1 (human) ( 814 ) , ARF GAP1 (human) ( 11 ) , CAB39 (human) ( 315 ) , caveolin-1 (human) ( 124 ) , CIP2A (human) ( 57 ) , Etk (human) ( 82 ) , FLCN (human) ( 74 ) , GSK3A (human) ( 35 ) , GSK3B (human) ( 35 , 56 ) , HRas (human) ( 933 ) , IL2RA (human) ( 1020 ) , LYN (human) ( 811 ) , MAGE-A6 (human) ( 46 ) , MAGEA3 (human) ( 46 ) , MEK1 (human) ( 933 ) , mTOR (human) ( 309 , 810 ) , PDK1 (human) ( 23 , 161 , 422 ) , PIK3CA (human) ( 422 ) , PIK3R2 (human) ( 21 ) , Pim1 (human) ( 20 ) , Pim2 (human) ( 20 ) , PKCA (human) ( 243 ) , PKD1 (human) ( 352 ) , PLK1 (human) ( 1043 ) , Raptor (human) ( 57 ) , RHEB (human) ( 1038 ) , RICTOR (mouse) ( 334 ) , SESN1 (human) ( 668 ) , SESN2 (mouse) ( 668 ) , TRAF2 (human) ( 45 ) , TRAF4 (human) ( 45 ) , TSC1 (human) ( 1037 , 1043 ) , TSC2 (human) ( 1037 , 1043 ) , ULK1 (human) ( 995 ) , ULK2 (human) ( 995 )
Putative in vivo kinases:
Akt1 (human) ( 54 ) , mTOR (human) ( 101 ) , p70S6K (human) ( 933 ) , p90RSK (human) ( 933 ) , PKCD (human) ( 1051 )
Kinases, in vitro:
p70S6K (human) ( 933 ) , p90RSK (human) ( 933 ) , RSK2 (human) ( 933 )
Putative upstream phosphatases:
PPP5C (human) ( 339 )
Treatments:
1-azakenpaullone ( 56 ) , 4-HT ( 814 ) , 5(S)-HETE ( 1060 ) , 5-HT ( 1041 ) , A-443654 ( 885 ) , acalabrutinib ( 22 ) , activin ( 91 ) , AG1478 ( 1053 ) , AG490 ( 1060 ) , alpelisib ( 27 ) , AMDE-1 ( 47 ) , amino_acid_starvation ( 57 , 74 ) , amino_acids ( 74 , 334 , 536 ) , angiotensin ( 1053 ) , angiotensin_2 ( 1039 ) , anti-CD3/CD28 ( 1020 , 1054 ) , anti-HLA ( 810 ) , anti-IgM ( 24 ) , AR-A014418 ( 56 ) , arginine deprivation ( 12 ) , As2O3 ( 1031 ) , AZD8055 ( 19 , 38 , 349 ) , batimastat ( 1039 ) , BI2536 ( 193 ) , bisindolylmaleimide ( 1058 ) , bleomycin ( 339 ) , caffeine ( 174 ) , chrysin ( 14 ) , colforsin ( 100 , 1061 ) , compound 2 ( 161 ) , compound_7 ( 161 ) , CRM197 ( 1039 ) , dactolisib ( 194 ) , dinoprost ( 325 ) , DMSO ( 814 ) , EGF ( 10 , 25 , 80 , 244 , 367 , 1030 , 1039 ) , Epo ( 854 ) , erlotinib ( 96 ) , estradiol ( 1037 ) , exercise ( 1056 ) , fasting ( 62 ) , fluoromethylketone ( 933 ) , FTI277 ( 1037 ) , gefitinib ( 60 , 85 , 96 , 351 ) , GSK2334470 ( 23 ) , H-89 ( 100 ) , H2O2 ( 352 ) , heregulin ( 91 ) , IBMX ( 100 ) , ibrutinib ( 22 ) , idelalisib ( 24 ) , IFN-gamma ( 1057 ) , IGF-1 ( 43 , 91 , 1029 ) , imatinib ( 29 , 85 , 279 , 351 , 1050 ) , INK-128 ( 15 , 31 , 38 ) , insulin ( 62 , 334 , 348 , 422 , 933 , 1058 , 1061 , 1062 ) , ionizing_radiation ( 292 , 1044 ) , KPT-185 ( 48 ) , lapatinib ( 26 , 51 , 84 ) , leucine ( 112 ) , LJH685 ( 10 ) , LY294002 ( 51 , 91 , 334 , 335 , 1031 , 1036 , 1040 , 1051 , 1055 , 1057 , 1059 , 1060 ) , medium change ( 536 ) , metastatic potential ( 198 ) , metformin ( 880 ) , miR-451 ( 315 ) , MPA ( 1050 ) , nicotinamide ( 55 ) , nitric_oxide ( 131 ) , OSI-027 ( 98 , 279 ) , P529 ( 146 ) , palbociclib ( 30 ) , PD184352 ( 10 ) , PD98059 ( 1062 ) , PF-04691502 ( 112 ) , phorbol_ester ( 10 , 44 , 49 , 89 , 185 , 348 , 724 , 933 , 1058 , 1061 ) , PI-103 ( 112 , 132 , 334 ) , PP242 ( 26 ) , QLT0254 ( 1052 ) , RAD001 ( 132 ) , rapamycin ( 12 , 15 , 35 , 40 , 41 , 43 , 49 , 56 , 89 , 98 , 101 , 112 , 132 , 279 , 325 , 334 , 335 , 348 , 349 , 351 , 513 , 724 , 814 , 823 , 885 , 933 , 1031 , 1036 , 1037 , 1044 , 1051 , 1055 , 1057 , 1061 ) , retinoic_acid ( 54 , 1051 ) , RGD ( 1058 ) , ribociclib ( 23 ) , rosiglitazone ( 33 ) , SB202190 ( 367 ) , SB203580 ( 1036 ) , SB216763 ( 41 ) , SEL24-B489 ( 20 ) , seliciclib ( 1016 ) , sertraline ( 19 ) , serum ( 10 , 422 , 933 , 1036 , 1038 , 1059 ) , serum_starvation ( 15 , 74 , 352 , 536 ) , SGI-1776 ( 27 ) , SHP2_inhibitor ( 19 ) , SII_angiotensin_2 ( 245 ) , siRNA ( 811 , 1038 , 1043 ) , Su11274 ( 85 , 351 ) , SU6656 ( 814 ) , temsirolimus ( 194 ) , testosterone ( 124 ) , Torin1 ( 38 , 49 , 74 , 101 ) , trichostatin_A ( 55 ) , U0126 ( 49 , 185 , 244 , 325 , 348 , 351 , 367 , 854 , 933 , 1036 , 1058 ) , vanadate ( 1059 ) , vemurafenib ( 39 ) , wortmannin ( 244 , 351 , 1037 , 1058 ) , XL413 ( 19 )

Downstream Regulation
Effects of modification on S6:
activity, induced ( 350 ) , enzymatic activity, induced ( 350 ) , molecular association, regulation ( 933 )
Effects of modification on biological processes:
cell growth, induced ( 45 , 124 ) , signaling pathway regulation ( 112 , 124 )
Induce interaction with:
RNA ( 933 )

Disease / Diagnostics Relevance
Relevant diseases:
Kaposi's sarcoma ( 121 ) , Status epilepticus ( 16 )

References 

1

Wang Y, et al. (2021) Phenotypic characterization of patients with activated PI3Kδ syndrome 1 presenting with features of systemic lupus erythematosus. Genes Dis 8, 907-917
34522717   Curated Info

2

van der Vlist M, et al. (2021) Signaling by the inhibitory receptor CD200R is rewired by type I interferon. Sci Signal 14, eabb4324
34637328   Curated Info

3

Amin AG, et al. (2021) Targeting the mTOR pathway using novel ATP‑competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma. Int J Oncol 59
34523696   Curated Info

4

Evans KW, et al. (2021) Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple negative breast cancer. Cancer Res
34518211   Curated Info

5

Lupse B, et al. (2021) Inhibition of PHLPP1/2 phosphatases rescues pancreatic β-cells in diabetes. Cell Rep 36, 109490
34348155   Curated Info

6

Kirstein AS, et al. (2021) PTEN regulates adipose progenitor cell growth, differentiation, and replicative aging. J Biol Chem 297, 100968
34273354   Curated Info

7

Gómez Tejeda Zañudo J, et al. (2021) Cell line-specific network models of ER+ breast cancer identify potential PI3Kα inhibitor resistance mechanisms and drug combinations. Cancer Res
34257082   Curated Info

8

Zhang EB, et al. (2021) Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. Oncogene
34247189   Curated Info

9

Mora S, Adegoke OAJ (2021) The effect of a chemotherapy drug cocktail on myotube morphology, myofibrillar protein abundance, and substrate availability. Physiol Rep 9, e14927
34197700   Curated Info

10

Cerezo EL, et al. (2021) RIOK2 phosphorylation by RSK promotes synthesis of the human small ribosomal subunit. PLoS Genet 17, e1009583
34125833   Curated Info

11

Meng D, et al. (2021) ArfGAP1 inhibits mTORC1 lysosomal localization and activation. EMBO J, e106412
33988249   Curated Info

12

Crump NT, et al. (2021) Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation. Cell Rep 35, 109101
33979616   Curated Info

13

Dai X, et al. (2021) Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol Cell
33909988   Curated Info

14

Chen J, et al. (2021) Chrysin serves as a novel inhibitor of DGK/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). Acta Pharm Sin B 11, 143-155
33532186   Curated Info

15

Mrozek EM, et al. (2021) Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer. PLoS One 16, e0248380
33891611   Curated Info

16

Reynolds CD, et al. (2020) Increased expression of Fragile X mental retardation protein in malformative lesions of patients with focal cortical dysplasia. Neuroreport 31, 1036-1041
32833881   Curated Info

17

Michalopoulou E, et al. (2020) Macropinocytosis Renders a Subset of Pancreatic Tumor Cells Resistant to mTOR Inhibition. Cell Rep
32101748   Curated Info

18

Wen PY, et al. (2020) First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. Clin Cancer Res
31937616   Curated Info

19

Wang C, et al. (2019) Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 574, 268-272
31578521   Curated Info

20

Szydłowski M, et al. (2017) Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. Blood 130, 1418-1429
28698206   Curated Info

21

Ito Y, Vogt PK, Hart JR (2017) Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β. Oncotarget 8, 55863-55876
28915558   Curated Info

22

Patel V, et al. (2017) Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res 23, 3734-3743
28034907   Curated Info

23

Jansen VM, et al. (2017) Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res 77, 2488-2499
28249908   Curated Info

24

Yang Q, et al. (2017) Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. Clin Cancer Res 23, 181-192
27342398   Curated Info

25

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

26

Morrison Joly M, et al. (2016) Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. Cancer Res 76, 4752-64
27197158   Curated Info

27

Iqbal A, et al. (2016) Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition. Oncotarget 7, 33192-201
27120806   Curated Info

28

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

29

Salizzato V, et al. (2016) Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. Oncotarget 7, 18204-18
26919095   Curated Info

30

Franco J, et al. (2016) Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. Cell Rep 14, 979-90
26804906   Curated Info

31

Li S, et al. (2016) Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. Oncogene 35, 642-50
25893295   Curated Info

32

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

33

Orlando UD, et al. (2015) Acyl-CoA synthetase-4, a new regulator of mTOR and a potential therapeutic target for enhanced estrogen receptor function in receptor-positive and -negative breast cancer. Oncotarget 6, 42632-50
26536660   Curated Info

34

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

35

Azoulay-Alfaguter I, et al. (2015) Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. Oncogene 34, 4613-23
25500539   Curated Info

36

Masui K, et al. (2015) Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proc Natl Acad Sci U S A 112, 9406-11
26170313   Curated Info

37

Shojaee S, et al. (2015) Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell 28, 114-28
26073130   Curated Info

38

Koo J, et al. (2015) mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation. Mol Cell Biol 35, 2344-55
25918246   Curated Info

39

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

40

Liu XD, et al. (2015) Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Oncogene 34, 2450-60
24998849   Curated Info

41

Koo J, et al. (2015) GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget 6, 8974-87
25797247   Curated Info

42

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

43

Chen L, et al. (2015) Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion. Oncotarget 6, 7136-50
25762619   Curated Info

44

Ni Y, et al. (2015) PKD1 is downregulated in non-small cell lung cancer and mediates the feedback inhibition of mTORC1-S6K1 axis in response to phorbol ester. Int J Biochem Cell Biol 60, 34-42
25578563   Curated Info

45

Ren HY, et al. (2015) Cytoplasmic TRAF4 contributes to the activation of p70s6k signaling pathway in breast cancer. Oncotarget 6, 4080-96
25738361   Curated Info

46

Pineda CT, et al. (2015) Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell 160, 715-28
25679763   Curated Info

47

Li M, et al. (2015) AMDE-1 is a dual function chemical for autophagy activation and inhibition. PLoS One 10, e0122083
25894744   Curated Info

48

Tabe Y, et al. (2015) Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185. PLoS One 10, e0137210
26340096   Curated Info

49

Leontieva OV, Blagosklonny MV (2014) Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion. Oncotarget 5, 12715-27
25587030   Curated Info

50

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

51

Axelrod MJ, et al. (2014) p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks. Cell Signal 26, 1627-35
24662264   Curated Info

52

Galan JA, et al. (2014) Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3. Proc Natl Acad Sci U S A 111, E2918-27
25002506   Curated Info

53

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

54

Bavelloni A, et al. (2014) Prohibitin 2 represents a novel nuclear AKT substrate during all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. FASEB J 28, 2009-19
24522204   Curated Info

55

Hong S, et al. (2014) Cross-talk between sirtuin and mammalian target of rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase 1 (S6K1) phosphorylation. J Biol Chem 289, 13132-41
24652283   Curated Info

56

Shin S, et al. (2014) Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. Oncogene 33, 1690-9
23584478   Curated Info

57

Puustinen P, et al. (2014) CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. J Cell Biol 204, 713-27
24590173   Curated Info

58

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

59

Ullal AV, et al. (2014) Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Sci Transl Med 6, 219ra9
24431113   Curated Info

60

Brobeil A, et al. (2014) The known interactome of PTPIP51 in HaCaT cells—inhibition of kinases and receptors. Int J Biochem Cell Biol 46, 19-31
24501773   Curated Info

61

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

62

Vendelbo MH, et al. (2014) Fasting Increases Human Skeletal Muscle Net Phenylalanine Release and This Is Associated with Decreased mTOR Signaling. PLoS One 9, e102031
25020061   Curated Info

63

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

64

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

65

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

66

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

67

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

68

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

69

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

70

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

71

Giansanti P, et al. (2013) Interrogating cAMP-dependent kinase signaling in Jurkat T cells via a protein kinase A targeted immune-precipitation phosphoproteomics approach. Mol Cell Proteomics 12, 3350-9
23882029   Curated Info

72

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

73

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

74

Petit CS, Roczniak-Ferguson A, Ferguson SM (2013) Recruitment of folliculin to lysosomes supports the amino acid-dependent activation of Rag GTPases. J Cell Biol 202, 1107-22
24081491   Curated Info

75

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

76

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

77

Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622   Curated Info

78

Rikova K (2013) CST Curation Set: 18531; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS*/T*) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759
Curated Info

79

Rikova K (2013) CST Curation Set: 18529; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS*/T*) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759
Curated Info

80

Tumurkhuu M, et al. (2013) A novel SOS1 mutation in Costello/CFC syndrome affects signaling in both RAS and PI3K pathways. J Recept Signal Transduct Res 33, 124-8
23528009   Curated Info

81

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

82

Chen S, et al. (2013) Tyrosine Kinase BMX Phosphorylates Phosphotyrosine-Primed Motif Mediating the Activation of Multiple Receptor Tyrosine Kinases. Sci Signal 6, ra40
23716717   Curated Info

83

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

84

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

85

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

86

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

87

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

88

Mulhern D (2012) CST Curation Set: 14049; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

89

Perl AE, et al. (2012) Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res 18, 1716-25
22167413   Curated Info

90

Mulhern D (2012) CST Curation Set: 13831; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate (P-S3-101) Rabbit mAb Cat#: 6967, PTMScan(R) Phospho-PKC Substrate Motif (K/RXS*XK/R) Immunoaffinity Beads Cat#: 6970
Curated Info

91

Singh AM, et al. (2012) Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 10, 312-26
22385658   Curated Info

92

Mulhern D (2012) CST Curation Set: 13112; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

93

Zhou J (2012) CST Curation Set: 13696; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

94

Zhou J (2012) CST Curation Set: 13697; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

95

Zhou J (2012) CST Curation Set: 13699; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

96

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

97

Mulhern D (2012) CST Curation Set: 13403; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

98

Gupta M, et al. (2012) Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119, 476-87
22080480   Curated Info

99

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

100

Xie J, et al. (2011) cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity. Cell Signal 23, 1927-35
21763421   Curated Info

101

Warfel NA, Niederst M, Newton AC (2011) Disruption of the interface between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2. J Biol Chem 286, 39122-9
21908613   Curated Info

102

Mulhern D (2011) CST Curation Set: 12760; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

103

Mulhern D (2011) CST Curation Set: 12742; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

104

Mulhern D (2011) CST Curation Set: 12743; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

105

Mulhern D (2011) CST Curation Set: 12744; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

106

Mulhern D (2011) CST Curation Set: 12745; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

107

Mulhern D (2011) CST Curation Set: 12746; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

108

Mulhern D (2011) CST Curation Set: 12747; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

109

Mulhern D (2011) CST Curation Set: 12748; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

110

Mulhern D (2011) CST Curation Set: 12750; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

111

Mulhern D (2011) CST Curation Set: 12751; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

112

Yuan J, et al. (2011) PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther 10, 2189-99
21750219   Curated Info

113

Mulhern D (2011) CST Curation Set: 12684; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

114

Mulhern D (2011) CST Curation Set: 12685; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

115

Mulhern D (2011) CST Curation Set: 12686; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

116

Mulhern D (2011) CST Curation Set: 12677; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

117

Mulhern D (2011) CST Curation Set: 12679; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

118

Mulhern D (2011) CST Curation Set: 12681; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

119

Mulhern D (2011) CST Curation Set: 12682; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

120

Mulhern D (2011) CST Curation Set: 12683; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

121

Roy D, Dittmer DP (2011) Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma. Am J Pathol 179, 2108-19
21819957   Curated Info

122

Mulhern D (2011) CST Curation Set: 12667; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

123

Mulhern D (2011) CST Curation Set: 12668; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

124

Bryant KG, et al. (2011) Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. Int J Biochem Cell Biol 43, 1318-29
21601007   Curated Info

125

Moritz A (2011) CST Curation Set: 12513; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

126

Guo A (2011) CST Curation Set: 12455; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)Xp[ST](I/L/V)
Curated Info

127

Guo A (2011) CST Curation Set: 12073; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

128

Guo A (2011) CST Curation Set: 12034; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTP
Curated Info

129

Guo A (2011) CST Curation Set: 12035; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTP
Curated Info

130

Moritz A (2011) CST Curation Set: 12260; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

131

Sarkar S, et al. (2011) Complex inhibitory effects of nitric oxide on autophagy. Mol Cell 43, 19-32
21726807   Curated Info

132

Mazzoletti M, et al. (2011) Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res 71, 4573-84
21602434   Curated Info

133

Guo A (2011) CST Curation Set: 12064; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

134

Moritz A (2011) CST Curation Set: 12040; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

135

Moritz A (2011) CST Curation Set: 12041; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

136

Moritz A (2011) CST Curation Set: 12042; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

137

Moritz A (2011) CST Curation Set: 12043; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

138

Moritz A (2011) CST Curation Set: 12044; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

139

Moritz A (2011) CST Curation Set: 12045; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

140

Moritz A (2011) CST Curation Set: 12046; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

141

Moritz A (2011) CST Curation Set: 12047; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

142

Moritz A (2011) CST Curation Set: 12048; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

143

Moritz A (2011) CST Curation Set: 12049; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

144

Moritz A (2011) CST Curation Set: 12050; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

145

Moritz A (2011) CST Curation Set: 12051; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

146

Xiang T, et al. (2011) Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene 30, 2443-50
21242970   Curated Info

147

Possemato A (2011) CST Curation Set: 11907; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

148

Moritz A (2011) CST Curation Set: 11933; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

149

Moritz A (2011) CST Curation Set: 11934; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

150

Moritz A (2011) CST Curation Set: 11935; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

151

Moritz A (2011) CST Curation Set: 11936; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

152

Moritz A (2011) CST Curation Set: 11937; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

153

Moritz A (2011) CST Curation Set: 11938; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

154

Moritz A (2011) CST Curation Set: 11939; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

155

Moritz A (2011) CST Curation Set: 11940; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

156

Moritz A (2011) CST Curation Set: 11944; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

157

Zhou J (2011) CST Curation Set: 11710; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

158

Guo A (2011) CST Curation Set: 11634; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

159

Guo A (2011) CST Curation Set: 11523; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

160

Guo A (2011) CST Curation Set: 11524; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

161

Nagashima K, et al. (2011) Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. J Biol Chem 286, 6433-48
21118801   Curated Info

162

Guo A (2011) CST Curation Set: 11452; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

163

Guo A (2011) CST Curation Set: 11283; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

164

Guo A (2011) CST Curation Set: 11284; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

165

Guo A (2011) CST Curation Set: 11285; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

166

Guo A (2011) CST Curation Set: 11298; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

167

Guo A (2011) CST Curation Set: 11375; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

168

Guo A (2011) CST Curation Set: 11379; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

169

Guo A (2011) CST Curation Set: 11380; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

170

Guo A (2011) CST Curation Set: 11384; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

171

Possemato A (2011) CST Curation Set: 11324; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

172

Possemato A (2011) CST Curation Set: 11326; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

173

Possemato A (2011) CST Curation Set: 11327; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

174

Saiki S, et al. (2011) Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. Autophagy 7, 176-87
21081844   Curated Info

175

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

176

Guo A (2011) CST Curation Set: 11115; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

177

Rikova K (2011) CST Curation Set: 11015; Year: 2011; Biosample/Treatment: cell line, NCI-H2073/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

178

Rikova K (2011) CST Curation Set: 11007; Year: 2011; Biosample/Treatment: cell line, LOU-NH91/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

179

Rikova K (2011) CST Curation Set: 11013; Year: 2011; Biosample/Treatment: cell line, NCI-H226/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

180

Rikova K (2011) CST Curation Set: 11014; Year: 2011; Biosample/Treatment: cell line, NCI-H1563/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

181

Rikova K (2011) CST Curation Set: 11010; Year: 2011; Biosample/Treatment: cell line, NCI-H661/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

182

Rikova K (2011) CST Curation Set: 11004; Year: 2011; Biosample/Treatment: cell line, NCI-H2342/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

183

Rikova K (2011) CST Curation Set: 11012; Year: 2011; Biosample/Treatment: cell line, NCI-H1666/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

184

Rikova K (2011) CST Curation Set: 11022; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

185

Carriere A, et al. (2011) ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 286, 567-77
21071439   Curated Info

186

Rikova K (2011) CST Curation Set: 10916; Year: 2011; Biosample/Treatment: cell line, NCI-H2170/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

187

Rikova K (2011) CST Curation Set: 10922; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

188

Rikova K (2011) CST Curation Set: 10886; Year: 2011; Biosample/Treatment: cell line, NCI-H2342/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

189

Rikova K (2011) CST Curation Set: 10904; Year: 2011; Biosample/Treatment: cell line, NCI-H226/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

190

Rikova K (2011) CST Curation Set: 11021; Year: 2011; Biosample/Treatment: cell line, NCI-H1944/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

191

Rikova K (2011) CST Curation Set: 10918; Year: 2011; Biosample/Treatment: cell line, NCI-H1651/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

192

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

193

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

194

Yang S, Xiao X, Meng X, Leslie KK (2011) A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 6, e26343
22039466   Curated Info

195

Possemato A (2010) CST Curation Set: 10960; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

196

Possemato A (2010) CST Curation Set: 10959; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

197

Ren H (2010) CST Curation Set: 10740; Year: 2010; Biosample/Treatment: cell line, OVKATE/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

198

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

199

Possemato A (2010) CST Curation Set: 10783; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

200

Possemato A (2010) CST Curation Set: 10790; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

201

Possemato A (2010) CST Curation Set: 10781; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

202

Possemato A (2010) CST Curation Set: 10789; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

203

Possemato A (2010) CST Curation Set: 10782; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

204

Possemato A (2010) CST Curation Set: 10787; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

205

Possemato A (2010) CST Curation Set: 10788; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

206

Possemato A (2010) CST Curation Set: 10785; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

207

Possemato A (2010) CST Curation Set: 10786; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

208

Possemato A (2010) CST Curation Set: 10792; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

209

Possemato A (2010) CST Curation Set: 10795; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

210

Possemato A (2010) CST Curation Set: 10791; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

211

Possemato A (2010) CST Curation Set: 10780; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

212

Possemato A (2010) CST Curation Set: 10794; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

213

Possemato A (2010) CST Curation Set: 10784; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

214

Possemato A (2010) CST Curation Set: 10838; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

215

Possemato A (2010) CST Curation Set: 10839; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

216

Possemato A (2010) CST Curation Set: 10777; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

217

Possemato A (2010) CST Curation Set: 10778; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

218

Possemato A (2010) CST Curation Set: 10776; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

219

Possemato A (2010) CST Curation Set: 10718; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

220

Possemato A (2010) CST Curation Set: 10716; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

221

Possemato A (2010) CST Curation Set: 10715; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

222

Possemato A (2010) CST Curation Set: 10714; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

223

Possemato A (2010) CST Curation Set: 10734; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

224

Possemato A (2010) CST Curation Set: 10726; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

225

Possemato A (2010) CST Curation Set: 10727; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

226

Possemato A (2010) CST Curation Set: 10730; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

227

Possemato A (2010) CST Curation Set: 10733; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

228

Possemato A (2010) CST Curation Set: 10728; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

229

Possemato A (2010) CST Curation Set: 10731; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

230

Possemato A (2010) CST Curation Set: 10729; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

231

Possemato A (2010) CST Curation Set: 10732; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

232

Moritz A (2010) CST Curation Set: 10617; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

233

Moritz A (2010) CST Curation Set: 10616; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

234

Moritz A (2010) CST Curation Set: 10602; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

235

Moritz A (2010) CST Curation Set: 10609; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

236

Moritz A (2010) CST Curation Set: 10614; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

237

Moritz A (2010) CST Curation Set: 10615; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

238

Moritz A (2010) CST Curation Set: 10613; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

239

Moritz A (2010) CST Curation Set: 10599; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

240

Moritz A (2010) CST Curation Set: 10600; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

241

Possemato A (2010) CST Curation Set: 10530; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

242

Possemato A (2010) CST Curation Set: 10531; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

243

Yang L, et al. (2010) TCR-induced Akt serine 473 phosphorylation is regulated by protein kinase C-alpha. Biochem Biophys Res Commun 400, 16-20
20691662   Curated Info

244

Aksamitiene E, et al. (2010) PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal 22, 1369-78
20471474   Curated Info

245

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

246

Possemato A (2010) CST Curation Set: 10291; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

247

Possemato A (2010) CST Curation Set: 10290; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

248

Possemato A (2010) CST Curation Set: 10293; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

249

Possemato A (2010) CST Curation Set: 10288; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

250

Possemato A (2010) CST Curation Set: 10292; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

251

Possemato A (2010) CST Curation Set: 10146; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

252

Possemato A (2010) CST Curation Set: 10160; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

253

Possemato A (2010) CST Curation Set: 10161; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

254

Possemato A (2010) CST Curation Set: 10158; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

255

Possemato A (2010) CST Curation Set: 10162; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

256

Possemato A (2010) CST Curation Set: 10156; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

257

Possemato A (2010) CST Curation Set: 10149; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

258

Possemato A (2010) CST Curation Set: 10154; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

259

Possemato A (2010) CST Curation Set: 10159; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

260

Possemato A (2010) CST Curation Set: 10152; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

261

Possemato A (2010) CST Curation Set: 10163; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

262

Possemato A (2010) CST Curation Set: 10148; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

263

Possemato A (2010) CST Curation Set: 10153; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

264

Possemato A (2010) CST Curation Set: 10151; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

265

Possemato A (2010) CST Curation Set: 10121; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

266

Possemato A (2010) CST Curation Set: 10111; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

267

Possemato A (2010) CST Curation Set: 10120; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

268

Possemato A (2010) CST Curation Set: 10119; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

269

Beausoleil S (2010) CST Curation Set: 10282; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

270

Beausoleil S (2010) CST Curation Set: 10279; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

271

Moritz A (2010) CST Curation Set: 10238; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

272

Moritz A (2010) CST Curation Set: 10235; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

273

Moritz A (2010) CST Curation Set: 10237; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

274

Moritz A (2010) CST Curation Set: 10241; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

275

Moritz A (2010) CST Curation Set: 10239; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

276

Moritz A (2010) CST Curation Set: 10242; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

277

Moritz A (2010) CST Curation Set: 10236; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

278

Moritz A (2010) CST Curation Set: 10231; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carci